Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Kinder Morgan Inc (KMI) Price & Performance

Heron Therapeutics IncTrade
Kinder Morgan IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Kinder Morgan Inc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Kinder Morgan Inc trades at $31.6 (market cap $69.90B). The key difference: Kinder Morgan Inc is far larger — about 1102.3× Heron Therapeutics Inc's market cap, and Kinder Morgan Inc pays a 3.76% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXKMI
Market Cap
$63.41M$69.90B
Sector
HealthEnergy
52-Week High
$1.49$34.31
52-Week Low
$0.32$25.84
Enterprise Value
$161.31M$101.95B
Dividend Yield
3.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Kinder Morgan Inc

Kinder Morgan (KMI) trades at $30.85, down 1.37% over the past day, with a bearish technical signal from moving averages and oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.37 versus $0.32 expected, and raised full-year guidance. Revenue for 2025 was $16.94 billion, with net income of $3.06 billion and a profit margin of 18.04%. Recent news highlights growth in natural gas infrastructure driven by LNG and power demand, supporting a dividend of $0.30 per share.

KMI presents a mixed outlook; fundamentals are solid with earnings beats and a robust project pipeline, but technical indicators signal near-term caution. Investment opportunities include dividend income and exposure to energy infrastructure growth, while risks involve debt levels and oil price volatility. Analyst consensus is nearly evenly split between buy and hold ratings, reflecting balanced sentiment amid macroeconomic uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Kinder Morgan Inc

Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.

Read more on KMI